Apart from the fact that a retrospective evaluation of BMi is not operative for providing this information at DLBCL diagnosis, evaluating the BM PET may be even more challenging during follow-up due to the high frequency of reactive uptake patterns, such as in the context of the systemic therapies administered (such as steroids, immunochemotherapy, or supportive treatment with granulocyte colony stimulating factor), driving false positive results. Here, CSF3 is linked to diffuse large B-cell lymphoma.